ロード中...
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
BACKGROUND: TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monother...
保存先:
| 出版年: | BMC Gastroenterol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8058969/ https://ncbi.nlm.nih.gov/pubmed/33879100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-021-01771-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|